United Therapeutics Corp (NASDAQ:UTHR) (Trend Analysis) shares were traded with a significant increase in volume. The stock closed last trading session at $129.25, down by -0.56%, with a volume of 942,441 shares against an average amount for the last three months of 550,574.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
United Therapeutics Corp (NASDAQ:UTHR) stock is currently trading 21.21% below its 52-week-high, 32.54% above its 52-week-low. The 1-year stock price history is in the range of $97.52 – $164.04. United Therapeutics Corp (UTHR) has a price to earnings ratio of 8.67 versus Healthcare sector average of 40.79. UTHR stock price has underperformed the Nasdaq by 23.5%. The Biotechnology company is currently valued at $5482.14 billion, and its share price closed the last trading session at $129.25. The stock has a 50-day moving average of $118.92 and a 200-day moving average of $116.46.
United Therapeutics Corp (UTHR) current short interest stands at 8.3 million shares. It has increased by 3% from the same period of last month. Around 23% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.62 million shares, the number of days required to cover the short positions stand at 13.4 days.
UTHR is forecasted to report earnings per share of $3.56 and a revenue of $420.2 million for the 4th Quarter of the fiscal year 2016. United Therapeutics Corp (UTHR) declared last quarter earnings on October 27. The Biotechnology company announced last quarter earnings per share of $3.63 against a consensus Street estimate of $3.47, beating the average estimate by $0.16. The company posted a revenue of $408.2 million compared to an estimation of $406.9 million.
Is this a Trading Opportunity? Click here for a free Trend Analysis Report
There are currently thirteen analysts that cover United Therapeutics Corp stock. Of those thirteen, four have a Buy rating, eight have a Hold rating and one has a Sell rating. On a consensus basis this yields to a Hold rating. The consensus target price stands at $128.75.
A recent analyst activity consisted of Ladenburg Thalmann upgrading their Neutral rating to Buy on October 28. Ladenburg Thalmann set their price target at $138. This corresponds to a 6.77% upside from the last closing price. On the date of report, the stock closed at $118.14.
H.C. Wainwright downgraded their Buy rating to Neutral on June 15, and decreased their price target from $175 to $95. This corresponds to a 26.5% downside from the last closing price. On the date of report, the stock closed at $104.51.
Another research firm was Argus Research who downgraded their Buy rating to Hold on May 24. On the date of report, the stock closed at $116.62.
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company’s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.